Brepocitinib

About Roivant Sciences

Founded in 2014, Roivant Sciences operates through a unique 'Vant' model, creating nimble subsidiary companies focused on specific therapeutic areas including Immunovant (autoimmune diseases), Priovant (severe autoimmune conditions), and Pulmovant (pulmonary diseases). The company has demonstrated strong execution with multiple successful Phase 3 trials and commercial launches, including VTAMA for plaque psoriasis. Roivant trades on NASDAQ under ticker ROIV and maintains a broad pipeline of investigational drugs across various therapeutic areas and development phases.

About Roivant Sciences

Founded in 2014, Roivant Sciences operates through a unique 'Vant' model, creating nimble subsidiary companies focused on specific therapeutic areas including Immunovant (autoimmune diseases), Priovant (severe autoimmune conditions), and Pulmovant (pulmonary diseases). The company has demonstrated strong execution with multiple successful Phase 3 trials and commercial launches, including VTAMA for plaque psoriasis. Roivant trades on NASDAQ under ticker ROIV and maintains a broad pipeline of investigational drugs across various therapeutic areas and development phases.

About Roivant Sciences

Founded in 2014, Roivant Sciences operates through a unique 'Vant' model, creating nimble subsidiary companies focused on specific therapeutic areas including Immunovant (autoimmune diseases), Priovant (severe autoimmune conditions), and Pulmovant (pulmonary diseases). The company has demonstrated strong execution with multiple successful Phase 3 trials and commercial launches, including VTAMA for plaque psoriasis. Roivant trades on NASDAQ under ticker ROIV and maintains a broad pipeline of investigational drugs across various therapeutic areas and development phases.

Therapeutic Areas